Home > Publications Database > Interferon-driven brain phenotype in a mouse model of RNaseT2 deficient leukoencephalopathy. > print

001     163450
005     20240302115204.0
024 7 _ |a 10.1038/s41467-021-26880-x
|2 doi
024 7 _ |a pmid:34764281
|2 pmid
024 7 _ |a pmc:PMC8586222
|2 pmc
024 7 _ |a altmetric:116626305
|2 altmetric
037 _ _ |a DZNE-2022-00210
041 _ _ |a English
082 _ _ |a 500
100 1 _ |a Kettwig, Matthias
|0 0000-0003-4804-7716
|b 0
245 _ _ |a Interferon-driven brain phenotype in a mouse model of RNaseT2 deficient leukoencephalopathy.
260 _ _ |a [London]
|c 2021
|b Nature Publishing Group UK
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1709309565_5353
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
500 _ _ |a (CC BY)
520 _ _ |a Infantile-onset RNaseT2 deficient leukoencephalopathy is characterised by cystic brain lesions, multifocal white matter alterations, cerebral atrophy, and severe psychomotor impairment. The phenotype is similar to congenital cytomegalovirus brain infection and overlaps with type I interferonopathies, suggesting a role for innate immunity in its pathophysiology. To date, pathophysiological studies have been hindered by the lack of mouse models recapitulating the neuroinflammatory encephalopathy found in patients. In this study, we generated Rnaset2-/- mice using CRISPR/Cas9-mediated genome editing. Rnaset2-/- mice demonstrate upregulation of interferon-stimulated genes and concurrent IFNAR1-dependent neuroinflammation, with infiltration of CD8+ effector memory T cells and inflammatory monocytes into the grey and white matter. Single nuclei RNA sequencing reveals homeostatic dysfunctions in glial cells and neurons and provide important insights into the mechanisms of hippocampal-accentuated brain atrophy and cognitive impairment. The Rnaset2-/- mice may allow the study of CNS damage associated with RNaseT2 deficiency and may be used for the investigation of potential therapies.
536 _ _ |a 352 - Disease Mechanisms (POF4-352)
|0 G:(DE-HGF)POF4-352
|c POF4-352
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
650 _ 7 |a Endoribonucleases
|0 EC 3.1.-
|2 NLM Chemicals
650 _ 2 |a Animals
|2 MeSH
650 _ 2 |a CD8-Positive T-Lymphocytes: metabolism
|2 MeSH
650 _ 2 |a Cognitive Dysfunction: genetics
|2 MeSH
650 _ 2 |a Cognitive Dysfunction: metabolism
|2 MeSH
650 _ 2 |a Disease Models, Animal
|2 MeSH
650 _ 2 |a Endoribonucleases: genetics
|2 MeSH
650 _ 2 |a Endoribonucleases: metabolism
|2 MeSH
650 _ 2 |a Female
|2 MeSH
650 _ 2 |a Flow Cytometry
|2 MeSH
650 _ 2 |a Genotype
|2 MeSH
650 _ 2 |a Humans
|2 MeSH
650 _ 2 |a Immunohistochemistry
|2 MeSH
650 _ 2 |a Leukoencephalopathies: genetics
|2 MeSH
650 _ 2 |a Leukoencephalopathies: metabolism
|2 MeSH
650 _ 2 |a Leukoencephalopathies: pathology
|2 MeSH
650 _ 2 |a Magnetic Resonance Imaging
|2 MeSH
650 _ 2 |a Male
|2 MeSH
650 _ 2 |a Memory T Cells: metabolism
|2 MeSH
650 _ 2 |a Mice
|2 MeSH
650 _ 2 |a Mice, Knockout
|2 MeSH
650 _ 2 |a Neuroglia: metabolism
|2 MeSH
650 _ 2 |a Real-Time Polymerase Chain Reaction
|2 MeSH
700 1 _ |a Ternka, Katharina
|0 0000-0003-3773-4625
|b 1
700 1 _ |a Wendland, Kristin
|b 2
700 1 _ |a Krüger, Dennis Manfred
|0 P:(DE-2719)2812548
|b 3
|u dzne
700 1 _ |a Zampar, Silvia
|0 0000-0003-0134-0974
|b 4
700 1 _ |a Schob, Charlotte
|b 5
700 1 _ |a Franz, Jonas
|0 0000-0001-7523-6622
|b 6
700 1 _ |a Aich, Abhishek
|0 0000-0001-8331-9874
|b 7
700 1 _ |a Winkler, Anne
|b 8
700 1 _ |a Sakib, M Sadman
|0 P:(DE-2719)2812054
|b 9
|u dzne
700 1 _ |a Kaurani, Lalit
|0 P:(DE-2719)2812832
|b 10
|u dzne
700 1 _ |a Epple, Robert
|0 P:(DE-2719)2812061
|b 11
|u dzne
700 1 _ |a Werner, Hauke B
|0 0000-0002-7710-5738
|b 12
700 1 _ |a Hakroush, Samy
|b 13
700 1 _ |a Kitz, Julia
|b 14
700 1 _ |a Prinz, Marco
|0 0000-0002-0349-1955
|b 15
700 1 _ |a Bartok, Eva
|0 0000-0003-0556-1950
|b 16
700 1 _ |a Hartmann, Gunther
|b 17
700 1 _ |a Schröder, Simone
|b 18
700 1 _ |a Rehling, Peter
|b 19
700 1 _ |a Henneke, Marco
|b 20
700 1 _ |a Boretius, Susann
|0 0000-0003-2792-7423
|b 21
700 1 _ |a Alia, A.
|b 22
700 1 _ |a Wirths, Oliver
|0 0000-0002-4115-0334
|b 23
700 1 _ |a Fischer, Andre
|0 P:(DE-2719)2000047
|b 24
|u dzne
700 1 _ |a Stadelmann, Christine
|0 P:(DE-2719)9000922
|b 25
|u dzne
700 1 _ |a Nessler, Stefan
|b 26
700 1 _ |a Gärtner, Jutta
|0 P:(DE-2719)2811933
|b 27
|u dzne
773 _ _ |a 10.1038/s41467-021-26880-x
|g Vol. 12, no. 1, p. 6530
|0 PERI:(DE-600)2553671-0
|n 1
|p 6530
|t Nature Communications
|v 12
|y 2021
|x 2041-1723
856 4 _ |u https://pub.dzne.de/record/163450/files/DZNE-2022-00210.pdf
|y OpenAccess
856 4 _ |u https://pub.dzne.de/record/163450/files/DZNE-2022-00210.pdf?subformat=pdfa
|x pdfa
|y OpenAccess
909 C O |o oai:pub.dzne.de:163450
|p openaire
|p open_access
|p VDB
|p driver
|p dnbdelivery
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 3
|6 P:(DE-2719)2812548
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 9
|6 P:(DE-2719)2812054
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 10
|6 P:(DE-2719)2812832
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 11
|6 P:(DE-2719)2812061
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 24
|6 P:(DE-2719)2000047
910 1 _ |a External Institute
|0 I:(DE-HGF)0
|k Extern
|b 25
|6 P:(DE-2719)9000922
910 1 _ |a External Institute
|0 I:(DE-HGF)0
|k Extern
|b 27
|6 P:(DE-2719)2811933
913 1 _ |a DE-HGF
|b Gesundheit
|l Neurodegenerative Diseases
|1 G:(DE-HGF)POF4-350
|0 G:(DE-HGF)POF4-352
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Disease Mechanisms
|x 0
914 1 _ |y 2021
915 _ _ |a Article Processing Charges
|0 StatID:(DE-HGF)0561
|2 StatID
|d 2021-02-02
915 _ _ |a Creative Commons Attribution CC BY (No Version)
|0 LIC:(DE-HGF)CCBYNV
|2 V:(DE-HGF)
|b DOAJ
|d 2021-02-02
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2021-02-02
915 _ _ |a Fees
|0 StatID:(DE-HGF)0700
|2 StatID
|d 2021-02-02
915 _ _ |a OpenAccess
|0 StatID:(DE-HGF)0510
|2 StatID
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1190
|2 StatID
|b Biological Abstracts
|d 2021-02-02
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2021-02-02
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b NAT COMMUN : 2021
|d 2022-11-11
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2022-11-11
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2022-11-11
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0501
|2 StatID
|b DOAJ Seal
|d 2021-10-13T14:44:21Z
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0500
|2 StatID
|b DOAJ
|d 2021-10-13T14:44:21Z
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b DOAJ : Peer review
|d 2021-10-13T14:44:21Z
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2022-11-11
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2022-11-11
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
|d 2022-11-11
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
|d 2022-11-11
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1040
|2 StatID
|b Zoological Record
|d 2022-11-11
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1060
|2 StatID
|b Current Contents - Agriculture, Biology and Environmental Sciences
|d 2022-11-11
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1150
|2 StatID
|b Current Contents - Physical, Chemical and Earth Sciences
|d 2022-11-11
915 _ _ |a IF >= 15
|0 StatID:(DE-HGF)9915
|2 StatID
|b NAT COMMUN : 2021
|d 2022-11-11
920 1 _ |0 I:(DE-2719)1440016
|k Bioinformatics and Genome Dynamics Core
|l Bioinformatics and Genome Dynamics Core
|x 0
920 1 _ |0 I:(DE-2719)1410002
|k AG Fischer
|l Epigenetics and Systems Medicine in Neurodegenerative Diseases
|x 1
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-2719)1440016
980 _ _ |a I:(DE-2719)1410002
980 _ _ |a UNRESTRICTED
980 1 _ |a FullTexts

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21